Organization | Lotus Labs

Lotus Labs Report issue

For profit Phase 1 Phase 2

Founded: Bangalore India (2001)

Status: Acquired by Actavis (2005) → now AbbVie (2019)

Organization Overview

First Clinical Trial

2004

NCT01131767

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Lotus Labs Private Limited | Lotus Labs Pvt. Ltd. | Lotus Labs Pvt. Ltd., | Lotus Labs Pvt. Ltd, Bangalore, India

Active Ingredients

Drugs in Phase 2 Trials (3)

inactivated rabies vaccine (Imovax) (1 trial)

mix of cr-57 and cr-4098 (1 trial)

rabies immune globulin (human) (HyperRAB) (1 trial)

Drugs in Phase 1 Trials (5)

aeras-402 (1 trial)

fluoxetine (prozac) (2 trials)

ibuprofen (motrin) (2 trials)

naproxen (naprosyn) (2 trials)

pseudoephedrine (Benylin) (4 trials)

Drugs in Other Trials (2)

adapalene (differin) (1 trial)

benzoyl peroxide (clearasil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Malnutrition (Phase 1)

Rabies (Phase 2)

Tuberculosis (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 10